Beam Therapeutics

Company Overview

Beam Therapeutics is a biotechnology company that offers a fully integrated platform for precision genetic medicines. Its gene editing technologies are centered around their proprietary base editing technology, which targets a single base in the genome without causing a double-stranded break in the DNA. Base editing is a method that uses a chemical reaction to create precise, predictable, and efficient genetic outcomes at the targeted sequence. Its proprietary base editors consist of two main components: CRISPR protein bound to a guide RNA that targets DNA without causing a double-stranded break, and a base editing enzyme, such as a deaminase, which performs the desired chemical modification of the target DNA base. It explores various delivery methods, including both ex vivo and in vivo approaches, tailored to different tissue types. The combination of base editing with tissue-specific delivery modalities forms a targeted, efficient, precise, and versatile gene-editing system capable of correcting, silencing, activating, and modifying genes, and simultaneously editing multiple genes.

Financial Highlights (FY 2025)

Company's Business Segments

• License and Collaboration Agreements : License and collaboration represents revenue recorded under the Lilly, Pfizer, Apellis, Orbital and Verve Agreements